Drug intelligence / Profile preview

CL-AT-313

Development stage: Preclinical
Lead developer: Charleston Laboratories
Modality: Small Molecules

Overview

**CL-AT-313** is a preclinical, confidential liquid fixed-dose combination being developed by Charleston Laboratories for symptomatic relief of cough and other symptoms associated with the common cold and upper respiratory allergies. The formulation contains an undisclosed antitussive plus other undisclosed active ingredients; its precise composition, molecular targets, and pharmacologic mechanism have not been publicly disclosed. ([charlestonlabs.com](https://charlestonlabs.com/therapeutic-focus/respiratory/))

Beyond the preview

Go deeper on CL-AT-313.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CL-AT-313.

Explore the full profile